Development of the Patient-Reported Impact of Dermatological Disease (PRIDD) measure: Delphi study

Nasim Tahmasebi Gandomkari; Nirohshah Trialonis-Suthakharan; Maria José Valencia López, MD; Rachael Pattinson; Chris Bundy, MD; Matthias Augustin, MD

OVERVIEW

Abstract:

Introduction: Due to the lack of patient input in existing dermatology measures, the Global Research on the Impact of Dermatological Diseases (GRIDD) project aims to develop a new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure alongside patients to comprehensively capture the burden of dermatological conditions. Our qualitative concept elicitation study developed a conceptual framework of impact to form the basis of PRIDD item generation. The next step and the aim of this study is to seek consensus from a wider pool of people with dermatological conditions on the validity of the concepts elicited and their prioritisation for inclusion in PRIDD.

Material and Methods: We conducted two rounds of a modified Delphi study. Adults (≥ 18 years) with dermatological conditions were recruited through the International Alliance of Dermatology Patient Organizations’ global membership network. The survey consisted of a demographics questionnaire and 263 items generated from the concept elicitation study.

Results: 1154 people representing 90 dermatological conditions across 65 countries participated. Based on the consensus criteria, qualitative feedback, and subgroup analyses, the 263 items were either removed, edited or added on a case-by-case basis. The outcome was the first draft of PRIDD containing five domains and 27 items.

Discussion: The large and diverse sample strengthens our confidence in the conceptual framework and Delphi findings. The 27 items form the basis of the first draft of PRIDD, which is currently being pilot tested with patients. Clinicians could use PRIDD in the future to better guide discussions with patients during consultations.

ATTACHMENTS: Tahmasebi_PeDRA2021_GRIDD poster_Final